BioNTech to Acquire Biotheus to Boost Oncology Strategy - Yahoo …
1 day ago · Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential ...
BioNTech signs agreement to acquire Biotheus - Yahoo Finance
14 hours ago · BNTX. BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a programmed death-ligand 1 and vascular endothelial growth factor A ...
BioNTech pays $800M to take control of potential Keytruda killer
1 day ago · Now, the biotech has struck a deal to gain full control of PM8002, a bispecific also known as BNT327. BioNTech is paying $800 million and committing up to $150 million in milestones to buy ...
BioNTech to Acquire Biotheus to Boost Oncology Strategy
1 day ago · BNT327/PM8002 has shown encouraging efficacy and tolerability in patients across various tumor types, with more than 700 patients treated in clinical trials to date.
BioNTech buys China's Biotheus to support oncology strategy
1 day ago · German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said ...
BioNTech to Acquire Biotheus for $800 Million to Expand …
1 day ago · BNTX. BioNTech SE (BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational ...
BioNTech Boosts Oncology Strategy With $800 Million+ China …
1 day ago · Zinger Key Points. BioNTech's acquisition of Biotheus includes $800M upfront and up to $150M in milestone payments. The deal grants BioNTech full rights to late-stage bispecific antibody BNT327 ...
BioNTech to acquire Biotheus for upfront consideration of $800M
2 days ago · The transaction is part of BioNTech’s oncology strategy, aimed at enhancing the company’s capabilities to research, develop and commercialize combination therapies using BNT327/PM8002.
BioNTech to Present Clinical Data Updates Across mRNA and ...
Sep 5, 2024 · BNT327/PM8002 is an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization for vascular normalization and immunostimulation in the microenvironment of the tumor.
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
1 day ago · BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. ... For More Such Health News, visit ...
- Some results have been removed